Citigroup expects that the stock price of CR Medical (01515) will have a negative reaction to its performance pressure.
According to the Zhixin Finance app, Citigroup released a research report stating that it rates CR Medical (01515) as 'buy' and expects that the stock price will have a negative reaction to its performance pressure, with a target price of HK$7. The bank is observing a 30-day downward catalyst and expects the company's first-half performance to disappoint the market, primarily due to potential devaluation of Huaiyin Hospital and slow revenue growth of CR Health (Liaoning) compared to expectations.
